A matter of importance: Prana has chosen PBT434 for Parkinson's to supplant PBT2 for AD. There is a reason for that: PBT2 has had it's chance to prove itself through the years but now time is up. Prana made a necessary choice. Experience has shown that trying to finance more than one investigative drug at a time is not feasible. Now starting over with available assets for a seemingly less questionable therapeutic is the only way to go.
The scientific world does not include PBT2 as having a place for AD. No suitors for merger or acquisition, no licensing, no interest in IMAGINE. NO PROGRESS.
Progress, page-34
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $4.579K | 1.526M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 749591 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 133062022 | 26 |
View Market Depth
| Last trade - 14.03pm 13/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |